American Society of Hematology

Figure 4

Plasmin degrades plasma- and platelet-derived FXIII-A*. Western blots against the FXIII A subunit. (A) Endogenous FXIII-A2* from human plasma after adding plasmin (3 µM) for various times. (B) FXIII-A2* from plasma with plasmin (3 µM) and α2-antiplasmin (5 µM) or TXA (7.5 mM). (C-D) Endogenous FXIII-A2/FXIII-A2* from platelets (PLT), 1 hour (C) and 16 hours (D) after exposure to thrombin, and incubating with various concentrations of plasmin. Samples contain combinations of Innovin (I), plasmin (P), α2-antiplasmin (A), and TXA (X). n = 3 for all experiments.

Plasmin degrades plasma- and platelet-derived FXIII-A*. Western blots against the FXIII A subunit. (A) Endogenous FXIII-A₂* from human plasma after adding plasmin (3 µM) for various times. (B) FXIII-A₂* from plasma with plasmin (3 µM) and α2-antiplasmin (5 µM) or TXA (7.5 mM). (C-D) Endogenous FXIII-A₂/FXIII-A₂* from platelets (PLT), 1 hour (C) and 16 hours (D) after exposure to thrombin, and incubating with various concentrations of plasmin. Samples contain combinations of Innovin (I), plasmin (P), α2-antiplasmin (A), and TXA (X). n = 3 for all experiments.

This Feature Is Available To Subscribers Only